Moleculin Biotech is trading 5.2% down today at $0.41 following a sharply discounted $9.3 million public offering that triggered a major dilution-driven selloff.
- The offering was priced at $0.75 per share with heavy warrant coverage, leading to significant warrant overhang and thin liquidity.
- The stock is continuing its post-offering weakness on August 4, 2026, as traders react to the dilution pressure and the influx of new shares into the market.